spacer
home > epc > spring 2009 > intelligent ecg
PUBLICATIONS
European Pharmaceutical Contractor

Intelligent ECG

SOME PROBLEMS SOLVED, NEW CHALLENGES INTRODUCED

Beginning in the late 1980s, a number of non-cardiac drugs have been linked to an increased risk of adverse cardiac events. Since late 2005, regulators require that all new drugs go through ECG-based cardiac safety testing (1). Prolongation of the QT interval on surface ECG is currently used as a surrogate marker of risk for the potentially lethal druginduced arrhythmia, torsades de pointes. The studies performed according to this guidance have been termed ‘Thorough QT’ (TQT) studies. A ‘positive TQT’ study means that the drug was found to prolong the QT interval in excess of the threshold for regulatory concern (upper 95 per cent confidence bound exceeding 10 msec).

Looking at the cardiac safety environment three years after the E14 guidance, it has become clear that, while some issues have been addressed, a new set of challenges has emerged. Greater focus from regulators and sponsors on cardiac safety is, undoubtedly, a good thing. The guidance has lead to the standardisation of ECG data collection and assessment in clinical trials, as well as to greater use of digital technologies. The FDA ECG warehouse now contains millions of ECGs collected from clinical development programmes, and it has become a foundation for ongoing FDA-academia-industry collaboration around advanced ECG analysis technology development and validation. Some breakthrough technologies have emerged from these efforts and are discussed in this article.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Alexandra (Sasha) Latypova is Executive Vice President and co-founder of iCardiac Technologies, a venture-backed company from the University of Rochester Medical Center. Prior to iCardiac Technologies, Sasha headed sales and business development at VirtualScopics, Inc. She had previously worked as a Manager in Healthcare practice at Analysis Group, Inc, where she advised pharmaceutical clients on a wide range of issues concerning product development, and provided economic analyses for pharmaceutical litigation cases. Sasha holds a Masters of Business Administration degree from the Amos Tuck School at Dartmouth College.

spacer
Alexandra Latypova
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

AirBridgeCargo expands its passive pharma solutions in partnership with SkyCell as it achieves the two-fold volume increase

AirBridgeCargo expands its passive pharma solutions in partnership with SkyCell as it achieves the two-fold volume increase AirBridgeCargo Airlines (ABC), one of the leaders in transportation of pharmaceutical products by air, and Zurich-based cold-chain ULD manufacturer SkyCell have sealed their partnership for the lease of all types of SkyCell containers to meet the demand for evolving volumes of passive pharmaceutical shipments, which reached around 3,500 tonnes for 1Q 2019 YOY and demonstrated a two-fold increase.
More info >>

White Papers

Industrial Security in the Pharmaceutical Sector

COPA-DATA

As an attractive target for cyber attacks, pharmaceutical companies need to understand cyber security, assess weak points and implement the appropriate security measures. This white paper describes some of the most effective industrial security tools pharmaceutical companies have at their disposal in the era of Industry 4.0.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement